Ann: Group Chief Financial Officer appointment-ADO.AX, page-2

• Mr Peter Harding-Smith, B Bus, CA appointed Group Chief Financial Officer and Company
Secretary of Anteo Diagnostics Limited and its Subsidiaries
• Strong experience in financial management and investor relations in ASX listed companies

Anteo Diagnostics Limited (ASX:ADO) announces the appointment of Mr Peter Harding- Smith to the
role of Group Chief Financial Officer for the Anteo Group.

Mr Harding-Smith brings a wealth of financial, governance and company secretarial experience to the
Anteo Group. He is a Chartered Accountant, a Fellow of the Governance Institute of Australia and
has over 10 years’ experience in ASX listed companies as Chief Financial Officer and Company
Secretary.

Mr Harding-Smith will take over from Mr Richard Martin, who will remain as a Non-executive Director
and Chair of the Audit Committee, and will be available to assist Mr Harding-Smith to ensure a
smooth transition. The Board wishes to thank Mr. Martin for long and dedicated service as CFO and
look forward to his continuing financial leadership on the Board of Directors.

Dr Jef Vangenechten said: “Peter joins Anteo at an important time. Peter’s history of delivery will
be invaluable in coordinating our efforts to realise the potential that Anteo technology offers.
With the recent appointment of Mrs Tamara Mills as COO of Brisbane operations and now Mr Peter
Harding-Smith as Group CFO, I believe Anteo has selected a high calibre team to transform our
vision into reality, attract more interest in the investor market, and yield deserving results for
shareholders.”

Mr Peter Harding-Smith said: “I’m keen to get started at Anteo, where the opportunities for growth
in a global business are very exciting. I’m looking forward to delivering on Anteo’s strategy and
growing solid market support for our business.”

The Board has agreed to issue Mr Harding-Smith’s with 2,000,000 options to acquire Fully Paid
Ordinary Shares as part of his package. These options will have an exercise period of 4 years, with
an exercise price based on 150% of the 10 day VWAP on the issue date and will vest one year from the date of issue.